Literature DB >> 11730149

Autistic disorders in Down syndrome: background factors and clinical correlates.

P Rasmussen1, O Börjesson, E Wentz, C Gillberg.   

Abstract

A study of a clinic-based sample of 25 individuals (12 females, 13 males; age at diagnosis 14.4 years, SD 7.4 years; age range 4 to 33 years) with Down syndrome (DS) and autism spectrum disorders, demonstrates that autism is by no means rare in DS. Results showed that there was a considerable delay in the diagnosis of autism as compared with children with autism who did not have DS. In 11 participants medical factors were identified that were likely to be of importance in contributing to the development of autism, and in four further participants there were factors of possible significance. Such factors include a history of autism or autism-related disorders in first- or second-degree relatives (n=5), infantile spasms (n=5), early hypothyroidism (n=3), evidence of brain injury after complicated heart surgery (n=2), or a combination of these factors. It is important that autism is recognised, identified, and fully assessed in individuals with DS in order for them to receive appropriate education and support.

Entities:  

Mesh:

Year:  2001        PMID: 11730149     DOI: 10.1017/s0012162201001372

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  11 in total

Review 1.  Autism spectrum disorder and epilepsy: Disorders with a shared biology.

Authors:  Bo Hoon Lee; Tristram Smith; Alex R Paciorkowski
Journal:  Epilepsy Behav       Date:  2015-04-19       Impact factor: 2.937

2.  The Effects of a Peer-Delivered Social Skills Intervention for Adults with Comorbid Down Syndrome and Autism Spectrum Disorder.

Authors:  Matthew A Cody Davis; Amy Spriggs; Alexis Rodgers; Jonathan Campbell
Journal:  J Autism Dev Disord       Date:  2018-06

Review 3.  Genetic and biologic classification of infantile spasms.

Authors:  Alex R Paciorkowski; Liu Lin Thio; William B Dobyns
Journal:  Pediatr Neurol       Date:  2011-12       Impact factor: 3.372

4.  Follow-up of children diagnosed with pervasive developmental disorders: stability and change during the preschool years.

Authors:  Sigrídur Lóa Jónsdóttir; Evald Saemundsen; Gudlaug Asmundsdóttir; Sigrún Hjartardóttir; Bryndís B Asgeirsdóttir; Hrafnhildur H Smáradóttir; Solveig Sigurdardóttir; Jakob Smári
Journal:  J Autism Dev Disord       Date:  2006-12-05

5.  The autistic phenotype in Down syndrome: differences in adaptive behaviour versus Down syndrome alone and autistic disorder alone.

Authors:  Anastasia Dressler; Valentina Perelli; Margherita Bozza; Stefania Bargagna
Journal:  Funct Neurol       Date:  2011 Jul-Sep

6.  Involvement of the HERV-derived cell-fusion inhibitor, suppressyn, in the fusion defects characteristic of the trisomy 21 placenta.

Authors:  Jun Sugimoto; Danny J Schust; Tomomi Yamazaki; Yoshiki Kudo
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

7.  Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach.

Authors:  Agnies M van Eeghen; Margaret B Pulsifer; Vanessa L Merker; Ann M Neumeyer; Elmer E van Eeghen; Ronald L Thibert; Andrew J Cole; Fawn A Leigh; Scott R Plotkin; Elizabeth A Thiele
Journal:  Dev Med Child Neurol       Date:  2012-12-04       Impact factor: 5.449

8.  Diagnosing Autism in Individuals with Known Genetic Syndromes: Clinical Considerations and Implications for Intervention.

Authors:  Susan L Hepburn; Eric J Moody
Journal:  Int Rev Res Dev Disabil       Date:  2011

9.  Co-occurring Down Syndrome and Autism Spectrum Disorder: Cognitive, Adaptive, and Behavioral Characteristics.

Authors:  Kathryn R Bradbury; Emily I Anderberg; Lark Huang-Storms; Iulia Vasile; Rachel K Greene; Susanne W Duvall
Journal:  J Autism Dev Disord       Date:  2021-04-27

10.  Early diagnosis of autism and impact on prognosis: a narrative review.

Authors:  Elisabeth Fernell; Mats Anders Eriksson; Christopher Gillberg
Journal:  Clin Epidemiol       Date:  2013-02-21       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.